🇮🇳 India
16h ago
Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid drag
Source ↗
👁 0
💬 0
Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lost Revlimid sales and pricing challenges. Lupin and Divi's are poised for strong performance, with Sun Pharma and Torrent showing resilience. Apollo Hospitals expects robust traction across its diverse segments.
Comments (0)